Currently, there are several C3 therapeutics in the preclinical and clinical stages of development (14), but only one anti-C3 motif has been approved for the treatment of PNH (Empaveli, pegcetacoplan injection) and GA (Syfovre, pegcetacoplan intraocular injection). Here, C3 is linked to paroxysmal nocturnal hemoglobinuria.